24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.

Abstract

AIM:

To compare the 24-h intraocular pressure (IOP) control obtained with the bimatoprost-timolol fixed combination (BTFC) versus latanoprost in newly diagnosed, previously untreated exfoliation syndrome (XFS) or exfoliative glaucoma (XFG) patients with baseline morning IOP greater than 29 mm Hg.

METHODS:

One eye of 41 XFS/XFG patients who met inclusion criteria was included in this prospective, observer-masked, crossover, comparison protocol. All subjects underwent a 24-h untreated curve and were then randomised to either evening administered BTFC or latanoprost for 3 months and then switched to the opposite therapy. At the end of each treatment period, patients underwent a treated 24-h IOP assessment.

RESULTS:

37 patients completed the trial. At baseline, mean untreated 24-h IOP was 31.1 mm Hg. Mean 24-h IOP with BTFC was significantly lower than with latanoprost (18.9 vs 21.2 mm Hg; p<0.001). Furthermore, BTFC reduced IOP significantly more than latanoprost at every time point, for the mean peak and trough 24-h IOP (p<0.001). There was no difference, however, in mean 24-h IOP fluctuation between the two medications (3.8 with BTFC vs 4.2 with latanoprost; p=0.161). Both treatments were well tolerated and there was no statistically significant difference for any adverse event between them.

CONCLUSIONS:

As first choice therapy in high-pressure, at-risk exfoliation patients, BTFC controlled mean 24-h IOP significantly better than latanoprost monotherapy.

• Authors: Anastasios-Georgios P Konstas, Gábor Holló, Dimitrios G Mikropoulos, Anna-Bettina Haidich, Antonios T Dimopoulos, Theodoros Empeslidis, Miguel A Teus, Robert Ritch
• Journal: The British journal of ophthalmology (Br J Ophthalmol) Vol. 97 Issue 7 Pg. 857-61 (Jul 2013) ISSN: 1468-2079 [Electronic] England
• PMID: 23686322 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Amides
• Antihypertensive Agents
• Drug Combinations
• Prostaglandins F, Synthetic
• Cloprostenol
• Latanoprost
• Timolol
• Bimatoprost

Topics

• Aged
• Aged, 80 and over
• Amides (adverse effects, therapeutic use)
• Antihypertensive Agents (adverse effects, therapeutic use)
• Bimatoprost
• Circadian Rhythm (drug effects)
• Cloprostenol (adverse effects, analogs & derivatives, therapeutic use)
• Cross-Over Studies
• Double-Blind Method
• Drug Combinations
• Exfoliation Syndrome (drug therapy, physiopathology)
• Female
• Glaucoma (drug therapy, physiopathology)
• Humans
• Intraocular Pressure (drug effects)
• Latanoprost
• Male
• Middle Aged
• Ocular Hypertension (drug therapy, physiopathology)
• Prospective Studies
• Prostaglandins F, Synthetic (adverse effects, therapeutic use)
• Timolol (adverse effects, therapeutic use)
• Tonometry, Ocular
• Treatment Outcome
• Visual Field Tests
• Visual Fields